Year : 2005  |  Volume : 47  |  Issue : 2  |  Page : 84--88

Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients


Ajit Avasthi1, Parmanand Kulhara1, Gagandeep Singh2, Rajni Sharma1, Rajinder P Kaur1 
1 Department of Psychiatry, Postgraduate Institute of Medical Education and Research Chandigarh, India
2 Department of Psychiatry Government Medical College and Hospital, Chandigarh, India

Correspondence Address:
Ajit Avasthi
Department of Psychiatry, Postgraduate Institute of Medical Education and Research Chandigarh 160012
India

Background: Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India. Aim: To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder. Methods: In this prospective study, patients (n=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Scale (MADRS). Results: Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile. Conclusion: Moclobemide is an effective antidepressant and is better tolerated than imipramine.


How to cite this article:
Avasthi A, Kulhara P, Singh G, Sharma R, Kaur RP. Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.Indian J Psychiatry 2005;47:84-88


How to cite this URL:
Avasthi A, Kulhara P, Singh G, Sharma R, Kaur RP. Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients. Indian J Psychiatry [serial online] 2005 [cited 2019 Sep 15 ];47:84-88
Available from: http://www.indianjpsychiatry.org/article.asp?issn=0019-5545;year=2005;volume=47;issue=2;spage=84;epage=88;aulast=Avasthi;type=0